259 related articles for article (PubMed ID: 12855653)
21. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
22. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
Liu TC; Wakimoto H; Martuza RL; Rabkin SD
Clin Cancer Res; 2007 Oct; 13(19):5897-902. PubMed ID: 17908985
[TBL] [Abstract][Full Text] [Related]
23. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
24. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
27. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
28. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
[TBL] [Abstract][Full Text] [Related]
29. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
31. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
Ino Y; Saeki Y; Fukuhara H; Todo T
Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
33. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
Fu X; Meng F; Tao L; Jin A; Zhang X
Gene Ther; 2003 Aug; 10(17):1458-64. PubMed ID: 12900760
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
[TBL] [Abstract][Full Text] [Related]
35. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
36. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
37. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
38. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer.
Benencia F; Courrèges MC; Conejo-García JR; Mohamed-Hadley A; Zhang L; Buckanovich RJ; Carroll R; Fraser N; Coukos G
Mol Ther; 2005 Nov; 12(5):789-802. PubMed ID: 15925544
[TBL] [Abstract][Full Text] [Related]
39. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
[TBL] [Abstract][Full Text] [Related]
40. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.
Ebert O; Harbaran S; Shinozaki K; Woo SL
Cancer Gene Ther; 2005 Apr; 12(4):350-8. PubMed ID: 15565179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]